MedTrace Logo

Immunogenicity of the Booster Dose of Two MenC Vaccines

NCT00392808 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 389

Last updated 2013-10-11

Study results available
· View outcomes & findings →

Summary

The purpose of the study is to evaluate the immune response of toddlers, to a booster dose in the second year of life of two meningococcal C conjugated polysaccharide vaccine, and to assess the interchangeability of the two different vaccines.

Conditions

  • Meningococcal Infection

Interventions

BIOLOGICAL

conjugated polysaccharide menC vaccine

Booster vaccine dose at 14 to 18 months.

Sponsors & Collaborators

  • Centro Superior de Investigación en Salud Publica

    lead OTHER_GOV

Principal Investigators

  • Javier Diez-Domingo, PhD · Centro Superior Investigacion Salud Publica (CSISP)

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
14 Months
Max Age
19 Months
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2007-01-31
Primary Completion
2008-05-31
Completion
2009-05-31

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00392808 on ClinicalTrials.gov